209 related articles for article (PubMed ID: 22927761)
1. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
2. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.
Sun T; Wang Y; Wang Y; Xu J; Zhao X; Vangveravong S; Mach RH; Xia Y
Adv Healthc Mater; 2014 Aug; 3(8):1283-91. PubMed ID: 24677807
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel.
Li X; Tian X; Zhang J; Zhao X; Chen X; Jiang Y; Wang D; Pan W
Int J Nanomedicine; 2011; 6():1167-84. PubMed ID: 21852896
[TBL] [Abstract][Full Text] [Related]
4. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
5. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.
Huang Y; Yang T; Zhang W; Lu Y; Ye P; Yang G; Li B; Qi S; Liu Y; He X; Lee RJ; Xu C; Xiang G
Int J Nanomedicine; 2014; 9():4581-95. PubMed ID: 25302024
[TBL] [Abstract][Full Text] [Related]
6. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells.
Banerjee R; Tyagi P; Li S; Huang L
Int J Cancer; 2004 Nov; 112(4):693-700. PubMed ID: 15382053
[TBL] [Abstract][Full Text] [Related]
7. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q
J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
[TBL] [Abstract][Full Text] [Related]
9. The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.
Gao W; Lin Z; Chen M; Yang X; Cui Z; Zhang X; Yuan L; Zhang Q
Int J Nanomedicine; 2014; 9():3425-37. PubMed ID: 25092974
[TBL] [Abstract][Full Text] [Related]
10. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
[TBL] [Abstract][Full Text] [Related]
11. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting.
Zhang H; Xiao Y; Cui S; Zhou Y; Zeng K; Yan M; Zhao C
J Nanosci Nanotechnol; 2015 Jun; 15(6):4058-69. PubMed ID: 26369013
[TBL] [Abstract][Full Text] [Related]
12. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal.
Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG
ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795
[TBL] [Abstract][Full Text] [Related]
13. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
14. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
15. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
[TBL] [Abstract][Full Text] [Related]
17. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.
Li N; Fu T; Fei W; Han T; Gu X; Hou Y; Liu Y; Yang J
J Pharm Pharmacol; 2019 Aug; 71(8):1243-1254. PubMed ID: 31215039
[TBL] [Abstract][Full Text] [Related]
19. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
20. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
